FDA approves BioMarin rare metabolic disorder drug, shares rise

(Reuters) - U.S. regulators on Thursday approved BioMarin Pharmaceutical Inc's Palynziq for adults with phenylketonuria, a rare metabolic disorder, sending shares of the biotechnology company up 3 percent after hours.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news